• West Pharmaceutical Services announced that its Board had appointed former Thermo Fisher Scientific executive Michel Lagarde as President, CEO and Director, with Lead Independent Director Robert F. Friel becoming Board Chair as part of the leadership transition following Eric M. Green’s retirement effective August 31, 2026.
• This handover brings in a leader steeped in pharma services, private equity and audit oversight, potentially reshaping how West pursues higher‑margin drug containment and delivery opportunities.
• We will now examine how Michel Lagarde’s pharma services background may influence West’s existing investment narrative around higher-margin mix and contract services.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

West Pharmaceutical Services Investment Narrative Recap

To own West Pharmaceutical Services, you need to believe in its shift toward higher value drug containment and delivery, supported by growing GLP 1 exposure and a richer HVP mix. The appointment of Michel Lagarde as CEO from August 2026 does not materially change the near term focus, where execution on capacity, pricing and contract manufacturing mix, alongside ongoing restructuring and leadership transitions, remains the key catalyst and also a central operational risk.

Among recent announcements, the US$1,000,000,000 share repurchase authorization in February 2026 stands out, as it sits alongside higher 2026 sales and EPS guidance and reinforces how management is positioning West during this phase of mix upgrade and contract services expansion. For investors watching margins around contract manufacturing and the transition away from CGM work, this capital return decision provides useful context for how the Board views the company’s progress.

Yet behind the leadership change and capital returns, investors should be aware of the execution risk around restructuring and management turnover, especially as West...

West Pharmaceutical Services' narrative projects $3.8 billion revenue and $751.8 million earnings by 2029. This requires 6.1% yearly revenue growth and about a $209 million earnings increase from $542.7 million today.

Uncover how West Pharmaceutical Services' forecasts yield a $349.85 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span roughly US$205 to US$350 per share, underlining how far apart individual views can be. When you set this against the reliance on GLP 1 growth and higher margin HVP mix, it becomes even more important to compare several viewpoints before deciding how West’s story fits in your portfolio.

Explore 3 other fair value estimates on West Pharmaceutical Services - why the stock might be worth as much as 11% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your West Pharmaceutical Services research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free West Pharmaceutical Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate West Pharmaceutical Services' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.